Reelected for 4 consecutive years! Medicilon is on the list of "Top 20 Chinese R&D CRO Enterprises in 2023"

On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released and grandly awarded at the "2023 Conference on High Quality Development of Healthcare Industry & the Eight Summit for China Pharmaceutical R&D Innovation"! Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List. This is also the 4th consecutive year that Medicilon has won this honor!

Top 20 Chinese R&D CRO Enterprises in 2023.webp

The selection of "Top 20 Chinese R&D CRO Enterprises in 2023" list is strictly based on the 10 indicators such as company's annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, number of employees, number of employees growth, brand popularity and leader in subdivided fields. The list represents the highest level of China's pharmaceutical CRO/CDMO industry.

此博客中的热门博文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...

阅读全文

Shanghai Medicilon Inc.

搜索此博客